JCR Pharmaceuticals Co., Ltd. (4552.T)

607,00 0,00 (0,00%) Börsenschluss: 03:15PM JST

JCR Pharmaceuticals Co., Ltd.

3-19 Kasuga-cho
Ashiya 659-0021
Japan
81 7 9732 8591
https://www.jcrpharm.co.jp

Sektor(en): Healthcare
Branche: Drug Manufacturers - General
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Shin Ashida	Chairman, CEO & President	N/A	N/A	1943
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	N/A	N/A	N/A
Yutaka Honda	Senior Corporate Officer, Executive Director of Administration Div. & Director of Human Resources	N/A	N/A	N/A
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	N/A	N/A	N/A
Toru Ashida	Senior VP of Sales & Administration, Executive Director of Sales Division and Director	N/A	N/A	1968
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	N/A	N/A	N/A
Katsuya Nishino	Executive Vice President	N/A	N/A	1956
Hiroshi Yoshimoto	Senior Advisor	N/A	N/A	1951
Takayo Egawa	Corporate Officer & Director of International Affairs Office	N/A	N/A	N/A
Mr. Hiroyuki Sonoda Ph.D.	VP of Research & Corporate Strategy, Executive Director of Research Division and Director	N/A	N/A	1978

Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in JPY.

Beschreibung

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Corporate Governance

JCR Pharmaceuticals Co., Ltd.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.